Edesa Biotech, Inc.

EDSA • Biotechnology

$4.73

▼ -0.03 (-0.63%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$42.61M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 10.67Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:12 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.73

Change-0.63%

Shares Out9.01M

Market Cap$42.61M

Enterprise Value$32.27M

52W Range0.72 - 20.32

Beta1.08

P/E-3.02

P/B3.35

P/FCF-4.76

EV/EBITDA-2.26

EV/FCF-3.61

Price$4.73

Change-0.63%

Shares Out9.01M

Market Cap$42.61M

Enterprise Value$32.27M

52W Range0.72 - 20.32

Beta1.08

P/E-3.02

P/B3.35

P/FCF-4.76

EV/EBITDA-2.26

EV/FCF-3.61

Earnings Yield-33.10%

FCF Yield-21.01%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio10.67

Quick Ratio10.67

Volume45.93K

Avg Volume214.97K

EPS Surprise-0.25

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

94/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 10.67Weak profitability

Analyst view

Analyst sentiment and price target

EDSA

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 6/21/2010

Industry: Biotechnology

P/B i: 3.35

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.00

Current Ratio: 10.67

Quick Ratio: 10.67

Status: Good

Insider Transactions

Recent executive and insider activity

Nijhawan Pardeep

Transaction: 08/03/2026

BUY

Change

+5,324

Price

Not reported

Filing

08/04/2026

Type

BUY

Nijhawan Pardeep

Transaction: 07/02/2026

BUY

Change

+3,378

Price

Not reported

Filing

07/02/2026

Type

BUY

Nijhawan Pardeep

Transaction: 06/16/2026

BUY

Change

+153,550

Price

Not reported

Filing

06/16/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Nijhawan Pardeep	BUY	+5,324	Not reported	08/03/2026	08/04/2026
Nijhawan Pardeep	BUY	+3,378	Not reported	07/02/2026	07/02/2026
Nijhawan Pardeep	BUY	+153,550	Not reported	06/16/2026	06/16/2026
Nijhawan Pardeep	BUY	+1,671	Not reported	06/01/2026	06/01/2026
Liu Da David	BUY	+19,000	Not reported	05/27/2026	05/29/2026
Nijhawan Pardeep	BUY	+96,913	Not reported	05/27/2026	05/29/2026
Olson Charles V	BUY	+19,000	Not reported	05/27/2026	05/29/2026
Sistilli Carlo	BUY	+19,000	Not reported	05/27/2026	05/29/2026
Brooks Michael J	BUY	+64,609	Not reported	05/27/2026	05/29/2026
Weiler Peter J.	BUY	+64,609	Not reported	05/27/2026	05/29/2026
Chypyha Joan	BUY	+19,000	Not reported	05/27/2026	05/29/2026
MacDonald Sean Arthur	BUY	+19,000	Not reported	05/27/2026	05/29/2026
Marshall Patrick	BUY	+19,000	Not reported	05/27/2026	05/29/2026
Nijhawan Pardeep	BUY	+1,159	Not reported	05/01/2026	05/01/2026
Nijhawan Pardeep	BUY	+2,578	Not reported	04/01/2026	04/10/2026
Brooks Michael J	BUY	+2,000	$1.57	02/26/2026	03/11/2026
Nijhawan Pardeep	BUY	+10,000	$3.90	03/05/2026	03/06/2026
Nijhawan Pardeep	BUY	+10,000	$4.26	03/04/2026	03/05/2026
Nijhawan Pardeep	BUY	+10,000	$3.63	03/03/2026	03/04/2026
Nijhawan Pardeep	BUY	+1,000	$2.28	03/02/2026	03/03/2026

About the Company

Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Source - link

Peers

BRTX COCP DWTX ERNA EVGN IMNN IMRN OSRH SNSE TRAW

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company's public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

GlobeNewsWire

Edesa Biotech Announces Proposed Public Offering

GlobeNewsWire

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.

GlobeNewsWire

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's Chief Executive Officer and healthcare-focused investors. The PIPE is expected to close on or about June 15, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.24	-0.49	-0.25
2026-02-13	-0.28	-0.28	0
2025-12-12	-0.27	-0.32	-0.05
2025-08-08	-0.26	-0.25	0.01
2025-05-14	-0.3	-0.3	0
2025-02-14	-0.31	-0.48	-0.17
2024-12-13	-0.54	-0.29	0.25
2024-08-09	-0.58	-0.52	0.06
2024-05-10	-0.69	-0.58	0.11
2024-02-09	-1.21	-0.54	0.67
2023-12-15	-0.71	-0.6	0.11
2023-08-09	-1.19	-0.7	0.49